Peptide Synthesis Market Projected to Reach $1.54 Billion by 2031

Demand for specialized building blocks, such as protected amino acids and resins, remains a primary driver for the sector. North America continues to command the largest market share, currently holding approximately 41.8% of the landscape due to extensive R&D spending and established manufacturing infrastructure. While solid-phase synthesis remains the dominant technique, manufacturers are increasingly pivoting toward automated, high-throughput systems to manage complex sequences and diverse chemical modifications.

Strategic consolidation is reshaping the industry, with major players prioritizing capacity expansion and vertical integration to secure supply chains. Recent high-profile transactions, including the acquisition of PolyPeptide Group AG and investments in large-volume production facilities, reflect a broader shift toward scaling capabilities for next-generation therapeutic candidates like GLP-1 receptor agonists. As outsourcing trends persist, specialized service providers are capturing a larger portion of the revenue, focusing on rapid turnaround and consistent quality for increasingly intricate peptide formats.